Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis

Table 1 Patients’ baseline characteristics

Variable	Values
Age, yr (± SD)	63 ± 10
Male gender, n (%)	265 (81.3)
Non-cirrhotic liver, n (%)	41 (12.5)
Child Pugh A/B/C, n (%)	137 (42)/98 (30)/92 (28)
Etiology of liver disease, n (%)
Hepatitis C virus	99 (30.3)
Alcohol	77 (23.5)
NASH	35 (10.7)
Cryptogenic	37 (11.3)
Hepatitis B virus	22 (6.7)
Cholestatic1	4 (1.2)
Autoimmune	-
Hemochromatosis	6 (1.8)
Miscellaneous	36 (11.0)
Comorbidities, n (%)	141 (43.1)
Diabetes mellitus, n (%)	84 (25.7)
Ascites, n (%)
Mild	76 (23.3)
Moderate-severe	77 (23.5)
Encephalopathy, n (%)
Grade I-II	78 (23.8)
Grade III-IV	6 (1.8)
CSPH, n (%)	212 (64.8)
ECOG 0-2, n (%)	262 (80.1)

¹Cholestatic: Primary Biliary Cholangitis, Primary and Secondary Sclerosing Cholangitis. NASH: Non-alcoholic steatohepatitis; CSPH: Clinically significant portal hypertension defined as presence of at least one of the following: Ascites, gastroaesophaguel varices or hepatic encephalopathy.